These results provide strong evidence to suggest the possibility that SGLT2 inhibitor effects are potent enough to exert vascular protective effects in clinical settings; however, little evidence currently exists to show the clinical effects of SGLT2 inhibitors on vascular function and atherosclerosis in patients with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.